Paper40453079
Strategies for CRISPR-based knock-ins in primary human B cells and lymphoma cell lines.
Lund S and 5 others. Front Immunol, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Strategies for CRISPR-based knock-ins in primary human B cells and lymphoma cell lines. Papers, record 40453079. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40453079
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| CRISPR-Cas Systems | Major topic |
| Gene Knock-In Techniques | Major topic |
| Gene Editing | Major topic |
| B-Lymphocytes | Major topic |
| Lymphoma, Large B-Cell, Diffuse | Major topic |
| Humans | |
| Cell Line, Tumor |
Source PubMed
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29713087 | Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. | Nat Med | 2018 | https://conductscience.org/library/papers/29713087 | PubMed |
| 2 | 29259529 | Genome Editing: Past, Present, and Future. | Yale J Biol Med | 2017 | https://conductscience.org/library/papers/29259529 | PubMed |
| 3 | 33398341 | Dynamics and competition of CRISPR-Cas9 ribonucleoproteins and AAV donor-mediated NHEJ, MMEJ and HDR editing. | Nucleic Acids Res | 2021 | https://conductscience.org/library/papers/33398341 | PubMed |
| 4 | 32289277 | A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. | Cancer Cell | 2020 | https://conductscience.org/library/papers/32289277 | PubMed |
| 5 | 21699444 | Romidepsin: a novel histone deacetylase inhibitor for cancer. | Expert Opin Investig Drugs | 2011 | https://conductscience.org/library/papers/21699444 | PubMed |
| 6 | 35658124 | BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL. | Cancer Discov | 2022 | https://conductscience.org/library/papers/35658124 | PubMed |
| 7 | 26543202 | Quantitative nature of overexpression experiments. | Mol Biol Cell | 2015 | https://conductscience.org/library/papers/26543202 | PubMed |
| 8 | 31794945 | Metabolic control of B cell immune responses. | Curr Opin Immunol | 2020 | https://conductscience.org/library/papers/31794945 | PubMed |
| 9 | 37141112 | Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. | Cancer Discov | 2023 | https://conductscience.org/library/papers/37141112 | PubMed |
| 10 | 39535522 | Efficient CRISPR/Cas9 Knock-in Approaches for Manipulation of Endogenous Genes in Human B Lymphoma Cells. | Curr Protoc | 2024 | https://conductscience.org/library/papers/39535522 | PubMed |
| 11 | 33657296 | Diffuse Large B-Cell Lymphoma. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33657296 | PubMed |
| 12 | 11131974 | Overview of vector design for mammalian gene expression. | Mol Biotechnol | 2000 | https://conductscience.org/library/papers/11131974 | PubMed |
| 13 | 29925955 | A multiprotein supercomplex controlling oncogenic signalling in lymphoma. | Nature | 2018 | https://conductscience.org/library/papers/29925955 | PubMed |
| 14 | 33005303 | CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy. | Comput Struct Biotechnol J | 2020 | https://conductscience.org/library/papers/33005303 | PubMed |
| 15 | 29641966 | Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29641966 | PubMed |
| 16 | 17379808 | CRISPR provides acquired resistance against viruses in prokaryotes. | Science | 2007 | https://conductscience.org/library/papers/17379808 | PubMed |
| 17 | 38473704 | Current Strategies for Increasing Knock-In Efficiency in CRISPR/Cas9-Based Approaches. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38473704 | PubMed |
| 18 | 37215153 | Strategies for precise gene edits in mammalian cells. | Mol Ther Nucleic Acids | 2023 | https://conductscience.org/library/papers/37215153 | PubMed |
| 19 | 34456559 | Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing. | Biologics | 2021 | https://conductscience.org/library/papers/34456559 | PubMed |
| 20 | 36171658 | CRISPR-Cas9: A History of Its Discovery and Ethical Considerations of Its Use in Genome Editing. | Biochemistry (Mosc) | 2022 | https://conductscience.org/library/papers/36171658 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40453079
GET https://conductscience.org/api/papers/v1/40453079/references?page=2